Allakos inc ALLK.US Overview Analysis
ALLK AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ALLK Current Performance
7.02%
Allakos inc
10.92%
Avg of Sector
0.39%
S&P500
Top 10 High Relevance to ALLK
Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
---|---|---|---|---|---|---|---|
GNPX | Genprex inc | 1 | 2 | 2 | 1 | 1 | |
ACTU | Actuate therapeutics inc | - | 4 | - | - | 1 | |
LPTX | Leap therapeutics inc | 2 | 1 | 1 | 1 | 1 | |
CRGX | Cargo therapeutics inc | - | 1 | 1 | 3 | 1 | |
SGMO | Sangamo therapeutics inc | 3 | 2 | 4 | 1 | 1 |
- GNPX Genprex incValue 1Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
ALLK Profile
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company's most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.